Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonca-R in Unfit/Frail DLBCL
NCT05144009Phase 2Terminated
- Sponsor
- ADC Therapeutics
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 2, open-label trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL) and follicular lymphoma (FL) (2 cohorts), sponsored by ADC Therapeutics. Primary endpoints: Complete Response Rate up to 17.1 months and Percentage of Participants Who Completed 4 Cycles of Treatment up to 12 weeks. Started Jun 2022; status: terminated.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05144009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144009.